Global Leading Market Research Publisher QYResearch announces the release of its latest report “GMP Oligonucleotide Production – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global GMP Oligonucleotide Production market, including market size, share, demand, industry development status, and forecasts for the next few years.
Biopharmaceutical companies and academic research institutions face a persistent challenge: producing high-purity oligonucleotides (ASOs, siRNA, aptamers, and guide RNAs) that meet regulatory standards for safety, traceability, and batch-to-batch consistency. Non-GMP synthesis may suffice for early discovery but fails to satisfy FDA/EMA requirements for investigational new drug (IND) enabling studies, clinical trials, or commercial therapeutic launch. GMP Oligonucleotide Production solves this pain point by providing synthesis, purification, analytical testing, and formulation under strict Good Manufacturing Practice (GMP) standards, ensuring that products meet stringent requirements for quality, safety, and traceability, making them suitable for use in drug development, clinical trials, and large-scale commercial manufacturing of approved therapeutics. As over 100 oligonucleotide-based therapeutics advance through clinical pipelines and eight approved products (including Spinraza, Onpattro, and Leqvio) generate multi-billion dollar revenues, GMP-grade oligonucleotide production has become a critical capacity bottleneck and strategic outsourcing priority.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097906/gmp-oligonucleotide-production
1. Market Size, Growth Trajectory & Core Keywords
The global market for GMP Oligonucleotide Production was estimated to be worth US$ 375 million in 2025 and is projected to reach US$ 642 million, growing at a CAGR of 8.1% from 2026 to 2032. GMP oligonucleotide production refers to the synthesis, purification, analytical testing, and formulation of oligonucleotides under strict Good Manufacturing Practice (GMP) standards. The process ensures that the products meet stringent requirements for quality, safety, and traceability, making them suitable for use in drug development, clinical trials, and large-scale commercial manufacturing of approved therapeutics.
Core industry keywords integrated throughout this analysis include: GMP Oligonucleotide Production, Modified Primer Synthesis, Therapeutic Oligonucleotide Manufacturing, Drug Development Compliance, and CDMO Scale-Up.
2. Industry Segmentation: Biotech Company vs. Academic Research Institution Perspectives
From an end-user stratification viewpoint, demand for GMP oligonucleotide production differs notably between commercial biotech companies and academic research institutions:
- Biotech Companies (drug developers, emerging therapeutics firms): Require GMP-grade oligonucleotides for IND-enabling toxicology studies (GLP-compliant), Phase I-III clinical trial supply, and commercial launch. These clients demand full regulatory documentation (DMF filing support, certificate of analysis with 21 CFR Part 11 compliance), large-scale synthesis (1 gram to >10 kg per batch), and extensive analytical characterization (mass spectrometry, ion-exchange chromatography, capillary electrophoresis). Modified primer synthesis (2′-O-methyl, 2′-F, phosphorothioate backbones, locked nucleic acids) represents approximately 75% of commercial-stage demand due to enhanced stability and pharmacokinetic properties.
- Academic & Scientific Research Institutions: Typically require smaller quantities (micrograms to milligrams) for target validation, mechanistic studies, or early-stage lead optimization. While some academic projects use non-GMP material, those planning translational studies or IND filings increasingly seek “research-grade GMP” (pre-GMP) or small-scale GMP batches (1–100 mg). Price sensitivity is higher, but the volume of unique sequences requested is substantially greater than in commercial settings.
Segment by Type
- Common Primer Synthesis: Unmodified DNA/RNA oligonucleotides, standard phosphodiester backbones. Suitable for PCR primers, sequencing probes, and basic research.
- Modified Primer Synthesis: Chemically modified nucleotides (2′-OMe, 2′-F, PS backbone, LNA, morpholino, 5′-end modifications). Essential for therapeutic ASOs, siRNAs, and CRISPR guide RNAs requiring enhanced nuclease resistance and target affinity.
Segment by Application
- Biotech Company: Drug development, clinical trial supply, commercial therapeutic manufacturing.
- Academic Scientific Research Institution: Target validation, mechanistic studies, early lead optimization, translational research.
3. Recent Industry Data (Last 6 Months) & Policy Drivers
According to new data from the Oligonucleotide Therapeutics Society (OTS) annual survey and FDA’s Office of Therapeutic Products (OTP) tracking (Q1–Q3 2025):
- Global GMP oligonucleotide production volume (in grams) increased 18.6% year-over-year, driven by advancing late-stage clinical candidates for Duchenne muscular dystrophy (exon skipping), Huntington’s disease, and complement-mediated diseases.
- Modified primer synthesis now accounts for approximately 68% of total GMP oligonucleotide production value (up from 58% in 2023), with premium pricing of US$8,000–25,000 per gram compared to US$400–1,200 per gram for common primers.
- Average batch size for commercial-scale GMP production increased from 1.2 kg to 2.5 kg per campaign, as approved oligonucleotide drugs scale to meet market demand.
Policy impact: The FDA’s 2025 draft guidance on “Oligonucleotide Therapeutic Development – CMC Considerations” now mandates enhanced characterization of impurity profiles (including n-1, n-2 failure sequences and phosphorothioate diastereomer distribution) using high-resolution mass spectrometry. This has increased analytical testing costs by approximately 20–25% but reduced batch failure rates due to previously undetected purity issues. Additionally, the European Pharmacopoeia added three new oligonucleotide monographs in January 2026, standardizing quality specifications across EU member states.
4. Technical Challenges & Solution Differentiation
Three persistent technical barriers define competition in GMP oligonucleotide production:
- Scalability of modified primer synthesis: Solid-phase synthesis using phosphoramidite chemistry works efficiently at small scale (micromolar), but coupling efficiency decreases at multi-kilogram scale, especially for modified monomers with sterically hindered protecting groups. Leading CDMOs like Thermo Fisher Scientific and Merck employ continuous flow solid-phase synthesis and iterative coupling optimization to maintain >99.5% stepwise yield even for 2′-O-modified building blocks.
- Impurity removal and characterization: Failure sequences (shorter by 1–5 nucleotides), depurination products, and phosphorothioate diastereomers require orthogonal purification methods (ion-pair reverse-phase HPLC, anion-exchange chromatography). Advanced providers like TriLink BioTechnologies and Integrated DNA Technologies (IDT) have implemented two-dimensional liquid chromatography (2D-LC) systems reducing residual n-1 content below 0.5%.
- Regulatory data integrity for synthesis records: FDA expects full traceability from raw material receipt to final bulk drug substance, including column logs, amidite consumption records, and purification profiles. GMP facilities must operate electronic batch records (EBR) and validated chromatography data systems (CDS) with full audit trails.
Exclusive industry insight: A recent technical benchmark study (BioProcess International, August 2025) comparing nine GMP oligonucleotide CDMOs revealed that 40% of batches exceeding impurity specifications failed due to phosphorothioate diastereomer distribution issues, not traditional failure sequences. This has driven adoption of stereopure phosphorothioate synthesis platforms (e.g., Wave Life Sciences’ technology), with Azenta Life Sciences announcing a strategic partnership in Q4 2025 to offer stereopure GMP oligonucleotides at a 35% premium over standard PS-backbone products.
5. User Case Examples (Biotech vs. Academic Segments)
- Case 1 – Biotech company (commercial-stage rare disease): A mid-cap biotech developing an antisense oligonucleotide (ASO) for a neuromuscular disorder required GMP-grade material for a global Phase III trial (2,400 patients). Using Genscript’s commercial-scale GMP service, they produced 8.2 kg of modified primer (2′-MOE, PS backbone) across six 300 mmol synthesis columns. Analytical characterization identified and removed a previously undetected phosphodiester variant, reducing impurity levels from 1.8% to 0.3%. The trial completed enrollment three months ahead of schedule, avoiding an estimated US$12 million in delay costs.
- Case 2 – Academic research institution (translational neuroscience): A university research lab identified a promising splice-switching oligonucleotide for spinal muscular atrophy (SMA) and sought IND filing. Using Eurogentec’s small-scale GMP service (5 mg modified primer with 2′-OMe and PS backbone), they generated toxicology-grade material for GLP studies within 10 weeks at a cost of US$48,000—approximately one-third of the cost of a full-scale commercial CDMO. The IND was accepted by FDA in Q2 2025, enabling first-in-human studies.
6. Competitive Landscape (Selected Key Players)
The market is moderately concentrated, with a mix of global life science tools providers and specialized oligonucleotide CDMOs:
Thermo Fisher Scientific, Merck, Azenta Life Sciences, BBI Life Sciences, TriLink BioTechnologies, Aurigene Pharmaceutical Services, Integrated DNA Technologies (IDT), Cusabio, Macrogen, Synbio Technologies, Eurogentec, Genscript, Abace Biotechnology, Tsingke, Guangzhou RiboBio, Atantares, Wuhan GeneCreate Biological Engineering, Beyotime, General Biol, Veliterbio.
独家观察 (Exclusive strategic note): The market bifurcates into two distinct tiers: Tier 1 CDMOs (Thermo Fisher, Merck, IDT, TriLink) offering fully integrated services from early discovery through commercial launch with annual capacities exceeding 100 kg; Tier 2 regional providers (Tsingke, RiboBio, GeneCreate, General Biol) serving primarily academic and early-stage biotech clients in Asia-Pacific at 25–40% lower price points. However, capacity constraints are emerging: current global GMP oligonucleotide synthesis capacity (estimated at 150–180 kg annually) will need to grow by 12–15% annually through 2030 to meet projected clinical and commercial demand. This capacity gap is driving investments in new facilities (e.g., Merck’s US$140 million expansion in Darmstadt, announced September 2025) and adoption of enzymatic oligonucleotide synthesis as an alternative to traditional solid-phase methods.
7. Forecast Outlook (2026–2032)
The convergence of high-throughput synthesis platforms and real-time process analytical technology (PAT) will reshape the market by 2028. Over 30% of new GMP oligonucleotide production capacity is expected to feature continuous solid-phase synthesis (vs. traditional batch), reducing production cycle time by 50–70% and enabling just-in-time clinical supply. Biotech companies should prioritize CDMOs offering (1) in-process control for modified primer coupling efficiency, (2) orthogonal purification methods for challenging sequences (GC-rich, long-mer >60 nt), and (3) demonstrated regulatory inspection track record (FDA, EMA, PMDA). The shift toward personalized oligonucleotide therapeutics (ultra-rare diseases, patient-specific ASOs) will sustain demand for flexible small-scale GMP capacity alongside traditional large-scale commercial production, favoring CDMOs with modular, multi-product suites.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
